Chondrial Therapeutics: Zafgen, Inc. (NASDAQ:ZFGN) Files An 8-K Entry into a Material Definitive Agreement

On December 17, 2019, Zafgen, Inc. (“Zafgen”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among Chondrial Therapeutics, Inc., a privately held biotechnology company (“Chondrial”), Chondrial Therapeutics Holdings, LLC, the sole stockholder of Chondrial (“Holdings”) and Zordich Merger Sub, Inc., a wholly owned subsidiary of Zafgen (“Merger Sub”), to which Chondrial will be merged with and into Merger Sub (the “Merger”) at the effective time of the Merger, with Chondrial continuing after the Merger as the surviving company and a wholly-owned subsidiary of Zafgen.